Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Non-phase study NCT07414823

Walking Football for Axial Spondyloarthritis

Walking Football for Axial Spondyloarthritis — Active Not Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07414823.

📅 06 May 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT07414823
Start
2025-10-20
Completion
2026-03-15
ClinicaliQ Trial Snapshot
  • Walking Football for Axial Spondyloarthritis — Active Not Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07414823.
  • Walking football twice weekly may safely improve mobility, fitness and wellbeing in axial spondyloarthritis patients.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Axial spondyloarthritis (axSpA) is a long-term inflammatory condition affecting the spine. Patients with this condition can have pain and stiffness in their back and neck. NICE Guidelines recommend that these patients should follow a structured exercise programme with additional hydrotherapy, to maintain mobility and flexibility, so as to improve quality of life. While there is limited hydrotherapy provided in Portsmouth to approximately 40 axSpA patients via the National Axial Spondyloarthritis Society (NASS), there is no bespoke structured exercise programme for over 400 axSpA patients under the care of the Rheumatology…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Why is walking in the rain good for your mental health?
Mental Health / Psychiatry · BBC Health · 17 Apr 2026
Rain exposure during outdoor activity may provide additional mental health benefits beyond standard exercise, potentially through sensory stimulation and enhanced mindfulness effects…
View brief →
Clinical Brief
Newcastle’s Burn on mental health and importance of asking for help
Mental Health / Psychiatry · BBC Health · 11 May 2026
Community-led mental health initiatives, such as visible environmental prompts (painted benches), can facilitate informal peer conversations and help destigmatise mental health discussions…
View brief →
Clinical Brief
Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
Mental Health / Psychiatry · MHRA · 29 Apr 2024
Finasteride: reminder of the risk psychiatric side effects and of sexual side ef...
View brief →
Clinical Brief
Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction
Mental Health / Psychiatry · MHRA · 11 May 2026
The MHRA has identified suicidal thoughts and behaviours as a safety concern with finasteride and dutasteride, requiring additional risk minimisation measures in…
View brief →
Guideline
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
Mental Health / Psychiatry · 17 Mar 2026
Offer ruxolitinib cream as a treatment option for non-segmental vitiligo in patients aged 12 years and over who have involvement of
View guideline →
Clinical Brief
Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
Mental Health / Psychiatry · MHRA · 08 Jan 2026
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in…
View brief →